PETCT Imaging with Fluorine-18-AlphaVBeta6-Binding Peptide for Detecting and Monitoring Metastatic Non-Small Cell Lung Cancer with Brain Metastases

What this Trial Is About

Researchers are evaluating fluorine-18-AlphaVBeta6-BP 18F-v6-BP as a PET imaging agent for patients with non-small cell lung cancer NSCLC that has spread to the brain. The study aims to determine how sensitive and specific this imaging method is for detecting metastases compared to current standard scans. This research may help improve disease assessment in patients with metastatic NSCLC, including brain involvement. Participants will receive two intravenous injections of up to 10 millicurie mCi of 18F-v6-BP followed by PETCT scans lasting about 30 minutes, performed 60 minutes after injection. Patients will have this study scan at baseline along with standard imaging using 18F-FDG PETCT and brain MRI. After receiving their usual cancer treatment, they will undergo restaging with all three imaging types 8 to 12 weeks later. During the study, participants will be monitored through these imaging procedures and clinical assessments. Researchers will compare the new PETCT scans to immunohistochemistry results and standard imaging methods over up to six months. Safety and ability to tolerate the scans will be observed. The total study duration includes initial and follow-up imaging with standard care treatments in between.

Fluorine-18-AlphaVBeta6-Binding Peptide Positron Emission Tomography in Metastatic Non-Small Cell Lung Cancer